Johnson & Johnson: 138 Years of Pioneering Healthcare

Credit | Johnson & Johnson
Science and Technology Will Advance Human Health More in the Next Decade Than It Has in the Last Century, Says Joaquin Duato, Johnson & Johnson CEO

Johnson & Johnson was founded in 1886 and is now one of the largest healthcare companies in the world, consistently ranking among the top biotech and pharmaceutical companies based on market capitalisation.

Headquartered in New Jersey, US, but with its over 130,000 employees spanning the world, the company comprises two main businesses: J&J Innovative Medicine, and J&J MedTech, as well as subsidiaries including Band-Aid, Neutrogena, and Tylenol. 

Rooted in a belief that health is everything, Johnson & Johnson has developed strength in healthcare innovation to work towards its goal of building a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal.

The past of healthcare looking to the future

Johnson & Johnson is looking toward a future of transformational science, innovative technology and geographic expansion funded by a maintained multi-faceted and disciplined capital allocation strategy. Coming into 2024, the company is looking towards operational sales growth in the range of 5-6%.

“Science and technology will advance human health more in the next decade than it has in the last century, leading to more effective and personalised treatment, earlier intervention, and smarter, less invasive healthcare,” believes Joaquin Duato, Chairman and Chief Executive Officer. 

“The breadth of our scientific capabilities, diverse portfolio and robust pipelines uniquely positions Johnson & Johnson to be a leader in this next wave of innovation while delivering strong financial performance.”

Youtube Placeholder

Duato has been with Johnson & Johnson for over three decades, serving as Vice Chairman of the Executive Committee before becoming Jonhson & Johnson’s eighth CEO in January 2022 and Chairman in January 2023. Duato is Johnson & Johnson’s first CEO with dual citizenship, which he holds between the US and Spain. He has an MBA from ESADE in Barcelona, Spain, and a Master of International Management from Thunderbird School of Global Management in Phoenix, Arizona. Previously, he has served on the board of UNIXEF USA, as the Chairman of PhRMA and as an Advisory Board Member of Tsinghua University School of Pharmaceutical Sciences.

In his vision for Jonhson & Johnson, he isn’t just looking to the next technological developments — he is developing a vision for the company’s long term growth and success. 

“We’ve created a clear set of steps to reinvent the business guided by our North Star — saving and improving patient lives,” he says. 

“Today, when it comes to the vision for Johnson & Johnson, I’m once again looking 25 years out, steering toward a horizon where we have achieved transformational medical innovations.”


Make sure you check out the latest industry news and insights at Healthcare Digital and also sign up to our global conference series - Tech & AI LIVE 2024


Healthcare Digital is a BizClik brand 



Feature Articles

Healthcare Business roundup: Baxter, Sanofi & Eli Lilly

Baxter International to sell kidney care spin-off Vantive; Sanofi's consumer health unit ‘to be separated’; Eli Lilly to buy Morphic Holding for $3.2bn

Trane Technologies Helping US Hospitals Meet Climate Pledge

Christy Fetsch of Trane Technologies explains how the company is helping US hospitals meet White House sustainability pledges for US healthcare provision

Nestlé Health Science Targets Weight Loss Side-Effects

Nestlé Health Science launches nutrition initiative to counteract side effects of weight-loss drugs, including hollowed-out 'Ozempic Face'

Eli Lilly Alzheimer's Drug Kisunla Approved in US by FDA

WEF: Gender Health Gap 'Costs women 75mn years of Life'

Schneider: Swathe of NHS Failing to Measure Sustainability